Wildin Robert S, Giummo Christine A, Reiter Aaron W, Peterson Thomas C, Leonard Debra G B
Department of Pathology & Laboratory Medicine, University of Vermont Health Network and Robert Larner M.D. College of Medicine at the University of Vermont, Burlington, VT, United States.
Department of Pediatrics, University of Vermont Health Network and Robert Larner M.D. College of Medicine at the University of Vermont, Burlington, VT, United States.
Front Genet. 2022 Apr 25;13:867334. doi: 10.3389/fgene.2022.867334. eCollection 2022.
To realize the promise of genomic medicine, harness the power of genomic technologies, and capitalize on the extraordinary pace of research linking genomic variation to disease risks, healthcare systems must embrace and integrate genomics into routine healthcare. We have implemented an innovative pilot program for genomic population health screening for any-health-status adults within the largest health system in Vermont, United States. This program draws on key research and technological advances to safely extract clinical value for genomics in routine health care. The program offers no-cost, non-research DNA sequencing to patients by their primary care providers as a preventive health tool. We partnered with a commercial clinical testing company for two next generation sequencing gene panels comprising 431 genes related to both high and low-penetrance common health risks and carrier status for recessive disorders. Only pathogenic or likely pathogenic variants are reported. Routine written clinical consultation is provided with a concise, clinical "action plan" that presents core messages for primary care provider and patient use and supports clinical management and health education beyond the testing laboratory's reports. Access to genetic counseling is free in most cases. Predefined care pathways and access to genetics experts facilitates the appropriate use of results. This pilot tests the feasibility of routine, ethical, and scalable use of population genomic screening in healthcare despite generally imperfect genomic competency among both the public and health care providers. This article describes the program design, implementation process, guiding philosophies, and insights from 2 years of experience offering testing and returning results in primary care settings. To aid others planning similar programs, we review our barriers, solutions, and perceived gaps in the context of an implementation research framework.
为了实现基因组医学的前景,利用基因组技术的力量,并利用将基因组变异与疾病风险联系起来的研究的惊人速度,医疗保健系统必须接受基因组学并将其整合到常规医疗保健中。我们在美国佛蒙特州最大的医疗系统内为任何健康状况的成年人实施了一项创新的基因组人群健康筛查试点计划。该计划借鉴了关键的研究和技术进步,以在常规医疗保健中安全地提取基因组学的临床价值。该计划作为一种预防性健康工具,由初级保健提供者为患者提供免费的非研究性DNA测序。我们与一家商业临床检测公司合作,针对两个下一代测序基因panel,涵盖431个与高、低外显率常见健康风险以及隐性疾病携带者状态相关的基因。仅报告致病或可能致病的变异。提供常规书面临床咨询,并附有简洁的临床“行动计划”,其中呈现了供初级保健提供者和患者使用的核心信息,并支持超出检测实验室报告范围的临床管理和健康教育。在大多数情况下,免费提供遗传咨询服务。预定义的护理途径和获得遗传学专家的帮助有助于结果的合理使用。尽管公众和医疗保健提供者的基因组能力普遍不完善,但该试点测试了在医疗保健中常规、合乎伦理且可扩展地使用人群基因组筛查的可行性。本文描述了该计划的设计、实施过程、指导理念以及在初级保健环境中提供检测和返回结果的两年经验中的见解。为了帮助其他计划类似项目的人,我们在实施研究框架的背景下回顾了我们遇到的障碍、解决方案以及察觉到的差距。